FDA Ignoring Abuse-Deterrent Opioid Concerns, Suit Says
Inspirion Delivery Sciences LLC shouldn't be allowed to sell its abuse-deterrent opioid RoxyBond until the U.S. Food and Drug Administration has properly responded to two citizen petitions questioning its approval, a...To view the full article, register now.
Already a subscriber? Click here to view full article